Pharmacogenetics and existing therapies

WHO Drug Information

Volumn 17, Issue 2, 2003, Pages 84-91

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPRENOLOL; AMIODARONE; AMITRIPTYLINE; CLOMIPRAMINE; CLOZAPINE; CYTOCHROME P450; DESIPRAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DNA; FLECAINIDE; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; IMIPRAMINE; INDORAMIN; LEVOMEPROMAZINE; MAPROTILINE; MEXILETINE; MIANSERIN; NIMODIPINE; NORCITALOPRAM; NORTRIPTYLINE; OLANZAPINE; OXPRENOLOL; PAROXETINE; PERPHENAZINE; PROPRANOLOL; TIMOLOL; UNINDEXED DRUG;

ANGIONEUROTIC EDEMA; BLEEDING; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; DNA DETERMINATION; DRUG RESPONSE; GENE EXPRESSION; GENERAL PRACTITIONER; GENETIC POLYMORPHISM; HUMAN; MENTAL DISEASE; OUTCOMES RESEARCH; PHARMACOGENETICS; REVIEW; STROKE;

EID: 0042020361     PISSN: 10109609     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Motulsky, A.G. Drug reactions, enzymes, and biochemical genetics. Journal of the American Medical Association, 165:835-837 (1957).
2. Beutler, E. The hemolytic effect of primaquine and related compounds: a review. Blood 24:103-139 (1959).
3. Lazarou, J., Pomeranz, B.H., Corey, P.N. Incidence of adverse drug reactions in hospitalised patients: a meta-analysis of prospective studies. Journal of the American Medical Association, 279: 1200-1205 (1998).
4. Agostoni, A., Cicardi, M. Drug-induced angioedema without urticaria. Drug Safety, 24: 599-606 (2001).
5. Smith, N.L., Psaty, B.M., Pitt, B. et al. Temporal patterns in the medical treatment of congestive heart failure with angiotensin-converting enzyme inhibitors in older adults, 1989 through 1995. Archives of Internal Medicine, 158: 1074-1080 (1998).
6. Vleeming, W., van Amsterdam, J.G., Stricker, B.H. et al. ACE inhibitor-induced angioedema: incidence, prevention and management. Drug Safety, 18: 171-188 (1998).
7. Brown, N.J., Snowden, M., Griffin, M.R. Recurrent angiotensin-converting enzyme inhibitor-associated angioedema. Journal of the American Medical Association, 278: 232-233 (1997).
8. Dean, D.E., Schultz, D.L., Powers, R.H. Asphyxia due to angiotensin converting enzyme (ACE) inhibitor mediated angioedema of the tongue during the treatment of hypertensive heart diseases. Journal of Forensic Science, 46: 1239-1243 (2001).
9. Aithal, G.P., Day, C.P., Kesteven, P.J. et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet, 353: 717-719 (1999).
10. Johansson, I., Lundquist, E., Bertilsson, L. et al. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proceedings of the National Academy of Science, 90: 11825-11829 (1993).
11. Bertilsson, L., Dahl, ML, Sjöqvist F, Aberg-Wistedt A, Humble M, Johansson I, et al. Molecular basis for rational mega-prescribing in ultrarapid hydroxylators of debrisoquin. Lancet, 341: 363 (1993).
12. Krynetski, E.Y., Tai, H.L., Yates, C.R. et al. Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms. Pharmacogenetics, 6: 279-290 (1996).
13. Lennard, L., Lilleyman, J.S., Van Loon, et al. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet, 336: 225-229 (1990).
14. Daly, A.K. Pharmacogenetics of the major polymorphic metabolizing enzymes. Fundamental & Clinical Pharmacology, 17: 27-41 (2003).
15. Poolsup, N., Li Wan Po, A., Knight, T.L. Pharmacogenetics and psychopharmacotherapy. Journal of Clinical Pharmacology and Therapeutics, 25(3): 197-220 (2000).
16. Smeraldi, E., Zanardi, R., Benedetti, F. et al. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Molecular Psychaitry, 3(6): 508-511 (1998).
17. Zanardi, R., Benedetti, F., Di Bella, D. et al. Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. Journal of Clinical Psychopharmacollogy, 20(1): 105-107 (2000).
18. Kim, D.K., Lim, S.W., Lee, S. et al. Serotonin transporter gene polymorphism and antidepressant response. NeuroReport, 11(1): 215-219 (2000).
19. Arranz, M.J., Munro, J., Birkett, J. et al., Pharmacogenetic prediction of clozapine response. Lancet, 355: 1615-1616 (2000).
20. Lima, J.J., Mohamed, M.H., Self, T.H. et al. Importance of beta(2)adrenergic receptor genotype, gender and race on albuterol-evoked bronchodilation in asthmatics. Pulmonary and Pharmacology Therapeutics, 13(3), 127-134 (2000).
21. Palmer, L.J., Silverman, E.S., Weiss, S.T. et al. Pharmacogenetics of asthma. American Journal of Respiratory and Clinical Care Medicine, 165(7), 861-866 (2002).
22. Rae, J.M., Johnson, M.D., Lippman, M.E. et al. Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. Journal of Pharmacology and Experimental Therapy, 299: 849-857 (2001).
23. Shalev, U., Grimm, J.W., Shaham, Y. Neurobiology of relapse to heroin and cocaine seeking: A review. Pharmacology Reviews, 54: 1-42 (2002).
24. Association of the British Pharmaceutical Industry. ABPI compendium of data sheets and summaries of product characteristics 1999-2000. Datapharm Publications. London, 2000.
25. PDR Publications. 2003 Physicians and Desk Reference. 57th edition. USA.
26. Chou, W.H., Yan, F-X., de Leon, J. et al. Extension of a pilot study: impact from the cytochrome P450 2D6 (CYP2D6) polymorphism on outcome and costs in severe mental illness. Journal of Clinical Psychopharmacology, 20(2):246-251 (2000).